Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
NCT05727761Phase 2Recruiting
- Sponsor
- University of Minnesota
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pioglitazone, liquid metformin (Aspargo Labs) in oral leukoplakia, sponsored by University of Minnesota. Started Jan 2025; status: recruiting.
02
Drugs
pioglitazoneliquid metformin (Aspargo Labs)
03
Conditions
oral leukoplakia
Beyond the preview
Go deeper on NCT05727761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727761.